Abstract:The overexpression of human c-Met tyrosine kinase induces the tumor proliferation and migration. Commercial drug is still not available for inhibiting this target. The structure of human c-Met was simulated and validated by molecular modeling. Compounds from our laboratory database, including natural products and anticancer agents, were employed for the docking analysis. De Novo drug design was further performed for three compounds with highest DockScore value to discover the novel inhibitors. Through the adsorption, distribution, metabolism, excretion and toxicity (ADMET) descriptor, only compounds A2, B3, C2 and C5 were selected. Through the pharmacophore analysis, ARG1086, HIS1088, ARG1208, ASN1209, ALA1226, ARG1227, ASP1228, TYR1230, and GLU1233 were suggested as the key residues because of strong pharmacophore features. In addition, the pharmacophore features of candidates consisted with the active site properties. The added fragments produced the strong interaction with the surrounding residues and yielded hydrogen bonds (HBs). Thus, the interaction energy between the ligand and the receptor was enhanced. Besides, the values of several scoring functions (PLP1, PLP2, and DockScore) of candidates were comparatively higher than compounds A, B, C, and Kirin. According to the aforementioned analyses, compounds A, A2, B, B3, C, C2 and C5 were suggested as the potent c-Met inhibitors. Besides, the scaffolds of compounds A, B, and C provided the direction for further drug design.

Discovery of novel type II c-Met inhibitors based on BMS-777607.

Discovery Of Novel C-Met Inhibitors Bearing A 3-Carboxyl Piperidin-2-One Scaffold

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Design, Synthesis and Biological Evaluation of C-Met Kinase Inhibitors Bearing 2-Oxo-1,2-dihydroquinoline Scaffold

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.

Structure-based Design and Synthesis of Imidazo[1,2-A]pyridine Derivatives As Novel and Potent Nek2 Inhibitors with in Vitro and in Vivo Antitumor Activities

Enhancing the Cellular Anti-Proliferation Activity of Pyridazinones As C-Met Inhibitors Using Docking Analysis.

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3- b]pyridazine derivatives as dual c-Met/Pim-1 potential inhibitors with antitumor activity

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

Design and Synthesis of Novel Benzo[D]Oxazol-2(3h)-One Derivatives Bearing 7-Substituted-4-enthoxyquinoline Moieties As C-Met Kinase Inhibitors

Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives

Discovery of Novel Inhibitors for C-Met by Virtual Screening and Pharmacophore Analysis

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors